How to read this list
This is for founders choosing a first vertical, not operators adding a fifth. The saturated categories are saturated because they worked; these twelve are open because they are harder in some specific way: a lab workflow, a sensitive audience, a mixed payment model, a controlled substance. The difficulty is the moat. Each entry gives you the demand signal, competition density, a rough economics sketch, regulatory lift, and realistic time to launch on modern white-label infrastructure. Building the stack yourself adds months to every row.
| Niche | Demand signal | Competition | Regulatory lift | Time to launch |
|---|---|---|---|---|
| Menopause | Strong, compounding | Medium | Low-medium | 4-8 weeks |
| Women's testosterone | Fastest-growing hormone niche | Low | High | 8-12 weeks |
| Women's sexual health | Real, stigma-suppressed | Low | Medium | 6-10 weeks |
| Postpartum care | Persistent gap | Very low | Medium-high | 10-14 weeks |
| MASH / liver health | New-therapy era | Very low | Medium | 8-12 weeks |
| Sleep apnea + obesity | New indication, huge undiagnosed pool | Low-medium | Medium | 8-12 weeks |
| Post-GLP-1 maintenance | Largest patient pool forming | Very low | Low | 4-6 weeks |
| Derm / skincare Rx | Steady, creator-driven | Medium-high | Low | 4-6 weeks |
| Sleep and insomnia | Broad, chronic | Medium | Medium-high with controlled meds | 6-10 weeks |
| Digestive health | Large, underserved online | Low | Medium | 8-12 weeks |
| Migraine | Large, poorly served | Low-medium | Low-medium | 6-10 weeks |
| Longevity panels | Premium demand rising | Medium, rising | Medium | 8-12 weeks |
Updated September 22, 2026: retitled, added the 2026 pivots and closures (Hims' compounded semaglutide exit under the March 9 Novo deal, Medstra to Cuvo, Pack Health, Peptide Sciences, the OpenLoop breach), Wheel's August 1 pulse data (patients 43+ over 4 in 10 visits, async up 121 percent), the $19 billion menopause figure, the 14.6 percent microdosing share, and a profitability FAQ.
Women's health: the deepest open ground
1. Menopause
Demand grows on demographics alone: Bloomberg's Big Take sized "The $19 Billion Menopause Economy" on August 5, 2026, and Wheel's Mid-Year Pulse (August 1) has patients 43 and older at more than 4 in 10 visits, up from under 3 in 10 two quarters earlier. A few funded players exist (Midi passed a $1 billion valuation), but density is nothing like weight loss. Economics: $99-149 a month for HRT plus visits, with multi-year retention potential that makes this one of the best LTV profiles in DTC health. Regulatory lift is low-medium; the work is clinical credibility, not licensure exotica. Launch in 4-8 weeks; the full build is in our menopause program blueprint. Skip it if: you want a transactional funnel. This audience demands education-heavy, longitudinal care and punishes thin brands.
2. Women's testosterone
The fastest-growing hormone niche and almost nobody serves it well. Demand is loud in midlife-women communities; competition done responsibly is near zero. Economics: $100-200 a month with labs attached. The catch is regulatory: prescribing is off-label for women, testosterone is Schedule III, and the DEA telehealth flexibilities it rides on expire December 31, 2026, with the Special Registration final rule at OIRA since August 25 and expected around November. Plan 8-12 weeks with real clinical governance. Skip it if: you are a first-time founder without strong clinical leadership. This niche punishes shortcuts publicly.
3. Women's sexual health
The mirror image of the men's ED gold rush, still mostly unbuilt. Demand is real but stigma-suppressed, which favors discreet online care. Economics: medication plus coaching subscriptions in the $60-150 a month range. Regulatory lift is medium, and the practical constraint is advertising: sexual health creative is restricted on major ad platforms, so organic, creator, and community channels carry the load. 6-10 weeks to launch. Skip it if: your entire acquisition plan is paid social. Restricted categories reward brands that can grow without it.
4. Postpartum care
A persistent, well-documented gap: mental health, thyroid, pelvic floor, lactation support, all fragmented across systems that discharge mothers at six weeks. Competition is nearly nonexistent. The honest economics: an episode-of-care model with a 12-18 month LTV window at $49-129 a month, not a decade-long subscription. Regulatory lift is medium-high because mental health screening and escalation paths must be real. 10-14 weeks. Skip it if: you need long subscription tails. Design for episode economics and referral loops instead.
Metabolic adjacencies: drafting behind GLP-1
5. MASH / liver health
The first dedicated therapies and the GLP-1 spillover created a real category with a huge, mostly undiagnosed population and almost zero DTC competition. Economics: labs-first care with GLP-1-adjacent pricing and high-value patients, but lab COGS and follow-up cadence eat margin if unmanaged. Regulatory lift is medium: FIB-4 triage, specialist referral paths, real escalation. 8-12 weeks. Skip it if: you cannot operate a genuine lab workflow. This is not a questionnaire vertical.
6. Sleep apnea + obesity
Zepbound's OSA indication fused two categories, and the combined program is still rare: CPAP incumbents do not do weight, weight brands do not do sleep. Most OSA remains undiagnosed, so demand is structural. Economics: home sleep test plus GLP-1 plus follow-up makes for strong ARPU with a diagnostic gate that improves patient quality. Regulatory lift is medium, driven by diagnostics and device adjacency. 8-12 weeks. Skip it if: physical-world operations scare you. Tests and devices mean fulfillment complexity that pure-Rx programs never touch.
7. Post-GLP-1 maintenance
The largest patient pool in DTC health history is now cycling off GLP-1s over cost, coverage, or reached goals, and almost nobody sells them a next step. Competition is effectively zero; acquisition is cheap because nobody bids on maintenance intent. Economics: lower ARPU at $49-99 a month across lower-dose or non-GLP-1 medication, coaching, and labs, offset by long tails and low CAC. Regulatory lift is low. 4-6 weeks; the program design is in our maintenance vertical playbook. Two numbers say the pool is forming now: Evidation data reported April 24, 2026 put microdosing at about 14.6 percent of GLP-1 users, and Wheel's 83 percent weight-management retention for H1 2026 means most of those patients are still inside a program that could sell them the next step, and mostly is not. Skip it if: you need high ARPU on day one to fund paid acquisition. This niche wins on efficiency, not ticket size.
Quiet recurring-revenue Rx
8. Derm / skincare Rx
Steady demand, photo-based intake, and the best creator-channel fit in telehealth. Wheel's asynchronous volume is up 121 percent year over year (Mid-Year Pulse, August 1, 2026), and derm is the most async-friendly vertical on this list. The center of the market (acne) is crowded, but rosacea, melasma, and anti-aging edges are not. Economics: compounded topicals at $30-90 a month on 90-day cycles with strong margins and low support load. Regulatory lift is low. 4-6 weeks to launch. Skip it if: you cannot win on brand and creative. The product is undifferentiated; distribution and identity are the whole moat.
9. Sleep and insomnia
Broad, chronic, destigmatized demand, mostly served by apps rather than actual care. Economics: CBT-I programming plus non-controlled prescriptions at $40-90 a month. The fork in the road is the formulary: stay non-controlled and regulatory lift is modest; touch Schedule IV sleep medications and you inherit the same DEA cliff as every controlled program, with flexibilities expiring December 31, 2026. 6-10 weeks. Skip it if: your model depends on controlled prescriptions. Build non-controlled-first or wait for the special registration rules to settle.
10. Digestive health
IBS, reflux, and gut protocols affect enormous populations and remain strangely absent from DTC telehealth. Competition is low. Economics: mixed baskets of Rx, OTC, and dietary coaching at $50-120 a month, with retention driven by symptom tracking and protocol iteration. Regulatory lift is medium; the real lift is clinical protocol depth and GI escalation paths. 8-12 weeks. Skip it if: you want one-SKU simplicity. This vertical is protocol-heavy and support-heavy by nature.
11. Migraine
A large diagnosed population stranded between rushed primary care and year-long neurology waitlists. Competition is thin. The economics require honesty: modern CGRP drugs are expensive for cash pay, while generic triptans and preventives are cheap, so cash models work best on generics-forward bundles at $30-80 a month, with a plan for coverage support on the expensive tier. Regulatory lift is low-medium. 6-10 weeks. Skip it if: you cannot navigate mixed cash-and-insurance economics. Pure cash-pay caps you at the generics tier.
The premium data play
12. Longevity panels
Biomarker testing went mainstream and demand keeps climbing upmarket. Competition is medium and rising fast, which makes positioning matter more here than anywhere else on this list. Economics: high-AOV annual memberships in the hundreds of dollars with meaningful lab COGS, and the real margin lives in what the panel feeds: hormone, metabolic, and preventive programs. Regulatory lift is medium: incidental findings require clinician follow-up, not a PDF and a shrug. 8-12 weeks. Skip it if: your product is a results dashboard. Interpretation and follow-on care are the product; the panel is the intake.
Whichever niche you pick, pick one, launch it properly, and expand from evidence rather than instinct. Our treatments directory shows what we can stand up fast when you are ready to test the thesis.
What pivoted or closed in 2026
The list of what stopped working this year is as useful as the list of what is open.
| Company | What happened | When |
|---|---|---|
| Hims & Hers | Stopped compounded semaglutide and its ads under the March 9, 2026 Novo deal; its Q2 filing still lists "limited compounded" GLP-1 | March 2026 |
| Medstra | Rebranded to Cuvo, the white-label platform now quoting $997-$2,000 a month plus $25 per consult | 2026 |
| Truepill | Became Fuze Health | May 2025 |
| Pack Health | Ceased operations | October 2025 |
| Peptide Sciences | The "research use only" peptide vendor shut down | March 2026 |
| OpenLoop | Breach on January 7-8, 2026: 716,000 people, roughly 120 client companies | January 2026 |
Two of the six were businesses built on a single compounded molecule or on peptides sold outside the prescription channel; none of the twelve niches above depends on either. The OpenLoop line is the one we would show a founder choosing a platform: a vendor's security incident becomes your patient notification, so ask any platform how it disclosed its last one.
FAQ
Is telehealth business profitable? It can be, and the filings show where. Hims & Hers reported $753.2 million of Q2 2026 revenue (up 38 percent) at a 64 percent gross margin after moving to branded drugs, and LifeMD runs about 89 percent gross margin with its own pharmacy. For an independent program, our estimate is that 500 patients at $99-$149 a month clears platform, provider, and pharmacy costs with room for acquisition if retention stays near the 83 percent Wheel reported for weight management in H1 2026; the line-item version is in our unit economics benchmarks from public filings.
What is the best telehealth niche to start in 2026? It depends on your operating appetite. Menopause and post-GLP-1 maintenance offer the best demand-to-competition ratio for first-time founders, derm and maintenance are the fastest to launch at 4-6 weeks, and women's testosterone or MASH reward teams with real clinical depth. The saturated categories (GLP-1 weight loss, hair loss, men's ED) are the ones to avoid as a first vertical.
Which telehealth niches have the least competition in 2026? Postpartum care, MASH and liver health, post-GLP-1 maintenance, digestive health, and women's sexual health have the thinnest DTC competition. Each is open for a specific reason, such as lab workflows, sensitive audiences, or restricted advertising, and that difficulty is what keeps competitors out.
How long does it take to launch a niche telehealth program? On white-label infrastructure, questionnaire-based programs like derm or maintenance launch in 4-6 weeks, most lab-involved programs take 8-12 weeks, and sensitive or multi-disciplinary programs like postpartum run 10-14 weeks. Building the platform yourself adds months to every one of those figures.
Which telehealth niches carry controlled-substance risk? Women's testosterone (Schedule III) and insomnia programs using Schedule IV sleep medications both depend on DEA telehealth flexibilities that expire December 31, 2026, with the special registration rule still not final. Founders entering those niches need a non-controlled formulary option or an in-person fallback plan.